Soon, a Cochrane review documented GnRH agonist triggering as a well-established mode of OHSS prevention.18 Similarly, professional organizations echoed the same message: “... strong evidence that the use of a GnRH agonist trigger results in a significant reduction in the development of OHSS.”19 Finally, as of 2013, more than one-third of IVF cycles in Europe were triggered with GnRH agonist.20 The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.